BriaCell Therapeutics Corp. BCTX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
BriaCell Therapeutics Corp. (BCTX) is a healthcare company listed in the US with a market value of about $30M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -141%.
About BriaCell Therapeutics
BriaCell Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 8 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$35M | -$26M | -$5M | -$20M | -$27M | -$14M | -$4M | -$5M |
| Free cash flow | -$29M | — | -$25M | — | — | — | — | — |
| EPS (diluted) | $-4.00 | $-3.01 | $-0.55 | $-2.33 | $-3.07 | $-1.58 | $-0.46 | $-0.54 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -183.1% | -124.0% | — | — | -116.9% | -19.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does BriaCell Therapeutics pay a dividend?
Not currently.
Is BriaCell Therapeutics a good stock to buy?
We do not give buy or sell advice. BriaCell Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.